Teva and Eagle try to block Bendeka generic
01-07-2021
Fed Circuit affirms generic maker’s win over Eagle
11-05-2020
Eli Lilly and Eagle Pharma settle antitrust and infringement claims
18-12-2019
JHVEPhoto / shutterstock.com
The US Food and Drug Administration (FDA) has warned a US Court of Appeals for the DC Circuit decision awarding market exclusivity to Eagle Pharmaceuticals for a cancer drug will have “grave” consequences for patient access.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
FDA, Eagle Pharmaceuticals, Bendeka, bendamustine, orphan drug, DC Circuit, appeal, blood cancer
